BRAF-targeted therapy and immune responses to melanoma

Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in mice, supporting the therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngiow, Shin Foong, Knight, Deborah A, Ribas, Antoni, McArthur, Grant A, Smyth, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716742/
https://www.ncbi.nlm.nih.gov/pubmed/23894707
http://dx.doi.org/10.4161/onci.24462
_version_ 1782277589217312768
author Ngiow, Shin Foong
Knight, Deborah A
Ribas, Antoni
McArthur, Grant A
Smyth, Mark J.
author_facet Ngiow, Shin Foong
Knight, Deborah A
Ribas, Antoni
McArthur, Grant A
Smyth, Mark J.
author_sort Ngiow, Shin Foong
collection PubMed
description Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in mice, supporting the therapeutic potential of combining BRAF inhibitors with immunotherapy.
format Online
Article
Text
id pubmed-3716742
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-37167422013-07-26 BRAF-targeted therapy and immune responses to melanoma Ngiow, Shin Foong Knight, Deborah A Ribas, Antoni McArthur, Grant A Smyth, Mark J. Oncoimmunology Author's View Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in mice, supporting the therapeutic potential of combining BRAF inhibitors with immunotherapy. Landes Bioscience 2013-06-01 2013-05-09 /pmc/articles/PMC3716742/ /pubmed/23894707 http://dx.doi.org/10.4161/onci.24462 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Ngiow, Shin Foong
Knight, Deborah A
Ribas, Antoni
McArthur, Grant A
Smyth, Mark J.
BRAF-targeted therapy and immune responses to melanoma
title BRAF-targeted therapy and immune responses to melanoma
title_full BRAF-targeted therapy and immune responses to melanoma
title_fullStr BRAF-targeted therapy and immune responses to melanoma
title_full_unstemmed BRAF-targeted therapy and immune responses to melanoma
title_short BRAF-targeted therapy and immune responses to melanoma
title_sort braf-targeted therapy and immune responses to melanoma
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716742/
https://www.ncbi.nlm.nih.gov/pubmed/23894707
http://dx.doi.org/10.4161/onci.24462
work_keys_str_mv AT ngiowshinfoong braftargetedtherapyandimmuneresponsestomelanoma
AT knightdeboraha braftargetedtherapyandimmuneresponsestomelanoma
AT ribasantoni braftargetedtherapyandimmuneresponsestomelanoma
AT mcarthurgranta braftargetedtherapyandimmuneresponsestomelanoma
AT smythmarkj braftargetedtherapyandimmuneresponsestomelanoma

Ejemplares similares